Results 111 to 120 of about 121,851 (237)

Hemostasis [PDF]

open access: yesTransfusion Alternatives in Transfusion Medicine, 2004
Volker Kretschmer   +3 more
openaire   +1 more source

Impact of Recanalization on Liver Hypertrophy after Portal Vein Embolization and the Role of Re‐Embolization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This retrospective study of 249 patients undergoing hepatectomy after right portal vein embolization (PVE) demonstrated that major recanalization–defined as recanalization more than one segment within the embolized liver–was associated with impaired regeneration of the future liver remnant (FLR).
Masao Uemura   +9 more
wiley   +1 more source

Endoscopic Management of Malignancy-Related Gastrointestinal Bleeding: A Comprehensive Narrative Review. [PDF]

open access: yesMed Sci (Basel)
Salvi D   +9 more
europepmc   +1 more source

Smart Flexible Tactile Sensors: Recent Progress in Device Designs, Intelligent Algorithms, and Multidisciplinary Applications

open access: yesAdvanced Intelligent Discovery, EarlyView.
Flexible tactile sensors have considerable potential for broad application in healthcare monitoring, human–machine interfaces, and bioinspired robotics. This review explores recent progress in device design, performance optimization, and intelligent applications. It highlights how AI algorithms enhance environmental adaptability and perception accuracy
Siyuan Wang   +3 more
wiley   +1 more source

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett   +20 more
wiley   +1 more source

Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3‐Mutated AML: A FILO‐DATAML‐PETHEMA Real‐World Study

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3‐mutated acute myeloid leukemia (AML); however, real‐world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n ...
Gaspar Aspas Requena   +31 more
wiley   +1 more source

Home - About - Disclaimer - Privacy